

Date: May 25, 2026

Ref. No.: KDL/SE/013/2026-27

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation.

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above



Q4 FY2025-26 Result Presentation

One of **INDIA'S LARGEST** Integrated
Diagnostic Service Provider



Disclaimer

This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/likely events or circumstances.

190

CT/ MRI Centres

4,700+

Patient Collection
Centres

59 Mn+

Tests in
FY25-26

68

Million+

Patients Served
In Last 5 Years

147

Pathology Labs

18

States/UT

Presence in India

331

Districts

Presence
PAN India






Krsnaa Diagnostics is one of the **fastest growing and Integrated diagnostic service provider** which includes radiology, pathology and tele-radiology





Provides **quality** and inclusive diagnostic services at **affordable rates** across various segments with a focus on Public Private Partnership model

One of India's largest **NABH accredited tele-radiology reporting hub** with inherent capability & capacity to process X-rays, CT scans and MRI scans, serving patients at remotest locations

The workforce comprises **350+ radiologists, 100+ pathologists, and 3,000+ qualified professionals**, including clinicians, technicians and operators

Q4 FY26 Financial Performance

Particulars	Q4 FY26	Q4 FY25	Growth
Revenue	1,926	1,861	4% 
EBIDTA	559	545	3% 
EBIDTA Margin	29%	29%	- 
PAT	417	207	102% 
PAT Margin	22%	11%	1,051 bps 

Particulars	Q4 FY26	Q4 FY25	Growth
EPS	12.8	6.3	103% 
No. of Patient Served	4.8	4.7	1% 
NABL Accreditation (Pathology lab)	54	51	6% 
NABH Accreditation (Radiology Centre)	54	32	74% 

Note: 1. Financial results of the Company are best monitored on an annual basis, as there is a certain level of cyclicality in business, and specific quarter performance may be impacted by specific events in that quarter


2. EBIDTA is excluding CSR & ESOP, INR in mn except EPS, NABL & NABH

3. PAT includes fair valuation gain of the investment in Apulki Healthcare Private Limited, amounting to INR 221.75 million

Q4 FY26 – Network Update


A total of **51 Centers** and **1,167 collection centers** were operationalized in FY25-26

Radiology








Upon completion of our existing order book, we will have **200+ CT/MRI** centres, cementing our position as one of **Asia's Largest Radiology Players.**





Pathology



The Rajasthan project will grow our network to **7** Reference Labs, **41** Mother Labs, **249** Satellite Labs & **5,000+** Collection Centres — making us **India's Deeply Rooted** and **Widely Accessible** Pathology Service Provider.

FY25-26 Financial Performance

Particulars	FY25-26	FY24-25	Growth
Revenue	7,728	7,172	8% 
EBIDTA	2,149	1,958	10% 
EBIDTA Margin	28%	27%	69 bps 
PAT	1,013	776	31% 
PAT Margin	13%	11%	231 bps 

Particulars	FY25-26	FY24-25	Growth
EPS	30.9	23.6	31% 
No. of Patient Served	19.8	19.2	3% 
NABL Accreditation (Pathology lab)	54	51	6% 
NABH Accreditation (Radiology Centre)	54	31	74% 

Note: 1. Financial results of the Company are best monitored on an annual basis, as there is a certain level of cyclicality in business, and specific quarter performance may be impacted by specific events in that quarter

2. EBIDTA is excluding CSR & ESOP, INR in mn except EPS, NABL & NABH

3. PAT includes fair valuation gain of the investment in Apulki Healthcare Private Limited, amounting to INR 221.75 million in Q4 FY25-26

Driving Excellence Through Quality



**American College
of Radiology™**

India's 1st ACR Accredited
Company



India's 1st CAP Accredited Lab
at Government Facility



India's 1st NABH Accredited
Tele-Radiology Hub

Service Excellence Pioneers of Indian Diagnostic Industry

Driving Excellence Through Quality

54



National Accreditation Board of
testing's & Calibration Laboratories

54




National Accreditation Board for
Hospitals & Healthcare Providers


We are committed to delivering superior quality as our benchmark and proudly served **~4.8 mn patients** in Q4 FY26, driven by our continuous focus on excellence.

Presence - PAN India

Well Diversified Regional Revenue Mix



West South North East



India map for representation only, not to scale

Growth Influencer- Competitive Advantages



147 → 290+

Labs

4,700+ Collection Centers → 5,000+



190 → 200+

CT / MRI Centers

1,400+ X-ray Centers



24x7- 365 Days

Operations

Round-the-clock availability

KEY DIFFERENTIATORS



Affordable Diagnostics

Pocket-friendly prices for every patient



Best in Quality Protocols

Top quality standards across all labs in India



Diverse Patient Database

Extensive, trusted clinical data repository



Deeper Penetration

Accessibility from Metro, tier-1 to tier-4 locations.

Growth Drivers

POLICY TAILWINDSS

3.3% → 5%

Healthcare GDP
(by 2030)

\$1,522 Bn

Est. Indian Healthcare Industry Size
in FY29-30

₹1,017 Bn

MoHFW Budget
(Union Budget 2025-26)

₹42 Bn

PM-ABHIM
(FY 2025-26)

Sources: CareEdge Ratings report (April 2025); Rubix Industry Insights-HEALTHCARE SERVICES; MoHFW Budget (Union Budget 2025-26); PM-ABHIM (FY 2025-26)



Long Tenure

*Predictable & Long-term
Business outlook:*

- Radiology avg tenure term ~10+ years
- Pathology avg tenure term ~5+ years



Captive Consumer

*Government OPD & IPD patients
attributed to:*

- District Hospitals
- Subdistrict Hospitals
- Community Healthcare centres
- Primary Healthcare Centres, etc.



Cost Leadership

Cost Optimisation:

- Volume-driven economies of scale
- Building Efficiency



Skilled Human Resource

- 350+ qualified doctors
- 3,000+ skilled technicians
- 1,000+ professionals



Robust IT Infrastructure

*Advanced Fully Integrated IT
system:*

- In-house PACS & LIMS
- Synchronizing AI
- Multiple and multi-level automation



Operational Excellence

- Pathology: Common processing units for PPP and retail both
- Radiology: Common imaging centres for PPP and retail both

Our Pricing - “Everyone Can Afford”

Segment	Test	Competition 1	Competition 2	Competition 3	Krsnaa	% lower from competitors
Radiology	CT Brain	4,500	4,500	3,500	880	(75)%
Radiology	MRI Brain	8,000	8,250	7,000	1,340	(81)%
Pathology	CBC	250	250	200	37	(82)%
Pathology	Blood Sugar	85	80	70	20	(71)%
Pathology	Thyroid	500	550	550	55	(90)%
Pathology	Vitamin D	1,500	1,250	1,450	153	(89)%
Pathology	Vitamin B12	1,000	1,100	1,300	69	(95)%
Pathology	HbA1C	550	440	400	49	(88)%


By offering services at **over 70% below** market rates, Krsnaa Diagnostics is expanding access to millions across India — and still delivering industry alike EBITDA and PAT, proving that **scale, efficiency, and impact can go hand in hand.**

*Note:
Amounts are in INR.
Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information*



Patient Experience at Its Best

Growth Engine- Rajasthan Pathology



Kishangarh, Mother Lab




Alwar, Mother Lab

Actual centre images

Growth Engine- Rajasthan Pathology



Rawatsar, Hub Lab



Sawai Madhopur, Mother Lab

Actual centre images

Growth Engine- Rajasthan Pathology




Actual centre images




ESG Initiatives


ESG Initiatives



Solar system capable of generating **80 KW** of green energy



~1,77,000+ hours Learning and development programs for employees




Using Biodegradable bags for **BMW**



Workflow digitization eliminated the monthly need for 10,000+ paper




Effluent treatment plants for wastewater reduction




~23,000+ Lives touched through CSR Initiatives

Retail Summary


Retail Revenue (INR Mn)




Patient Count (Mn)




Test Volume (Mn)



Revenue Per Patient (INR)



Retail Revenue Contribution to Group Revenue



Forward Growth Horizon: Scale | Awareness | Technology



Pillar A: Scale & Modality Advantage

PPP-Based Ecosystem

● PPP Infrastructure Leverage

Existing CT/MRI/pathology labs deployed for PPP serve as the cost-base for retail — marginal revenue with minimal incremental fixed cost, delivering superior ROCE.

● Asset-Light Franchise Model

Partnerships with local operators, franchise models, and collection-centre networks enabling rapid expansion without heavy capital outlays.

● Hub-and-Spoke Architecture

Centralized reference labs processing samples from a satellite network ensure quality consistency and cost efficiency at scale.

● Home Collection Scale-Up

Expanding phlebotomist network; digital platform enables seamless booking, real-time sample tracking, and fast report delivery.

● 24/7 Accessibility

RPL brand positioned on availability, affordability, and reliability — differentiated from hospital-based and premium competitors.



Pillar B: Awareness

Aggregator & Platform Partnerships

● RPL on Health Platforms

Positioning RPL services on health-tech aggregators and insurance platforms — scalable B2B2C patient acquisition at low CAC

● Corporate Wellness

Integration into employee wellness programs with corporates and insurers — predictable recurring volume

● Home Collection App

Mobile-first booking with real-time tracking — frictionless diagnostic experience for urban and semi-urban consumers

● Preventive Health Packages

Customised wellness screening bundles targeting early detection — India's growing ₹2.98 Tr diagnostic TAM by FY30

● 30,000+ Doctor Network

Digital referral platform strengthening doctor engagement across 5 states for a sustained B2C funnel



Pillar C: AI-Enabled Diagnostics

Technology as a Scale Multiplier

● AI-Powered Radiology

Automated image analysis & AI-assisted CT/MRI reporting — improves throughput, reduces radiologist dependency

● Digital Pathology

AI-enabled interpretation for scalable, consistent results — virtual expert consultation across geographies

● Teleradiology Platform

Remote specialist reporting for PPP contracts in rural & under-served regions

● LIMS & Operations

Real-time tracking, quality control, and TAT optimisation across the hub-and-spoke network

● ACR & CAP Accreditation

First company in India to receive American College of Radiology accreditation — unmatched radiology credential along with CAP in pathology

Retail Forward Growth Journey

RPL Retail Scale-Up: Six Growth Engines

<p>ENGINE 1</p> <p>Strategic Expansion- Newer Geographies</p> <p>Scaling to 7 to 8 states, new cities, rural geographies, with new lines of business.</p>	<p>7 to 8 States</p>	<p>ENGINE 2</p> <p>Building Depth in Existing Network</p> <p>1,000+ dedicated retail centres across Tier-1, Tier-2, and Tier-3 markets — via own centres, franchise partners, and collection networks, which will contribute to more patient volume.</p>	<p>1,000+ Retail Centres</p>	<p>ENGINE 3</p> <p>Tapping Preventive & Wellness Space- Smart Report for Patient Education</p> <p>Customized integrated health screening packages targeting early disease detection — at an affordable price point in Tier-2 ,3, and 4 geographies to cater larger audience base</p>	<p>~10-15% Contribution to Retail Revenue</p>
<p>ENGINE 4</p> <p>Radiology Retail Penetration</p> <p>Leveraging the existing CT/MRI network (149 CT + 41 MRI centres, Q4 FY26) for retail volume.</p>	<p>200+ CT/MRI Centres (Target)</p>	<p>ENGINE 5</p> <p>Home Collection Scale-Up</p> <p>Expanding phlebotomist network across urban and rural areas; optimized logistics and lab processing for faster sample-to-report turnaround at doorstep.</p>	<p>20+ Cities with Home Collection Network</p>	<p>ENGINE 6</p> <p>Leveraging All Business Channels</p> <p>Mobile app, website bookings, and digital report delivery — reducing customer acquisition cost while improving patient experience and driving repeat usage.</p>	<p>Low CAC via Digital Channels</p>

Activities in Retail Business

Doctor Engagement Activities



Activities in Retail Business

Health Checkup Camp/Awareness Programs



Activities in Retail Business

Medical Conferences



Activities in Retail Business

Center Branding





Financial Performance

Consolidated Financial Performance

Particulars	Q4 FY 26		Q4 FY 25		Q3 FY 26		FY 26		FY 25	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	1,926		1,861		1,812		7,728		7,172	
Expenses										
Cost of Material Consumed	444	23%	415	22%	391	22%	1,790	23%	1,693	24%
Employee benefits expense	327	17%	320	17%	356	20%	1,387	18%	1,327	19%
Fees to hospitals and others	143	7%	174	9%	150	8%	617	8%	607	9%
Other expenses	453	24%	410	22%	440	24%	1,784	23%	1,587	22%
Total Expenses	1367	71%	1,319	71%	1,337	74%	5,578	72%	5,214	73%
Share of Profit/ (loss) of Associate	-	-	-	-	(1)	0%	-	0%	-	-
EBITDA Before CSR & ESOP	559	29%	542	29%	474	26%	2,149	28%	1,958	27%
CSR and ESOP	10	1%	12	1%	10	1%	31	0%	57	1%
EBITDA	549	29%	530	29%	464	26%	2,118	27%	1,901	27%
Less: Finance costs	121	6%	68	4%	78	4%	344	4%	247	3%
Less: Depreciation	226	12%	220	12%	227	13%	905	12%	883	12%
Add: Other income	314	16%	44	2%	38	2%	433	6%	255	4%
PBT	516	27%	286	15%	197	11%	1,302	17%	1,027	14%
Tax	100	5%	79	4%	44	2%	289	4%	251	4%
PAT	416	22%	207	11%	152	8%	1,013	13%	776	11%

Consolidated Financial Performance

(INR In Mn)



Assets

Mar 31, 2026 Mar 31, 2025

Non-current assets

Property, plant and equipment	6,516.27	6,674.34
Capital work-in-progress	2,080.72	29.63
Intangible assets	48.41	29.49

Financial assets

Investments	574.28	315.42
Other financial assets	358.74	1,182.77
Deferred tax asset (net)	50.44	33.33
Other non-current assets	1,224.90	406.25
Total non-current assets	10,853.76	8,671.23

Current assets

Inventories	266.57	294.76
-------------	--------	--------

Financial assets

Trade receivables	2,955.06	2,777.45
Cash and cash equivalents	302.22	38.46
Bank balances other than cash and cash equivalent	3,304.95	645.90
Other financial assets	313.20	282.89
Other current assets	241.40	105.26
Total current assets	7,383.40	4,144.72

Total Assets

18,237.16 **12,815.95**

Liabilities

Mar 31, 2026

Mar 31, 2025

Equity

Equity share capital	162.19	161.45
Other equity	9,641.69	8,666.25
Total equity	9,803.88	8,827.70

Liabilities

Non-current liabilities

Borrowings	4,371.44	185.04
Lease Liabilities	311.49	286.52
Other financial liabilities	666.10	208.29
Employee benefit obligations	32.01	28.61
Deferred Tax Liabilities	300.23	225.91
Other non-current liabilities	-	-
Total non-current liabilities	5,681.27	934.37

Current liabilities

Financial liabilities

Borrowings	533.61	1,470.38
Lease Liabilities	126.63	93.33
Trade payables	632.02	971.27
Other financial liabilities	1,251.23	371.14
Other current liabilities	90.96	54.17
Provision	86.07	55.77
Current Tax Liabilities (net)	31.49	37.82

Current liabilities **2,752.01** **3,053.88**

Total Liabilities **8,433.28** **3,988.25**

Total Equity and Liabilities

18,237.16 **12,815.95**

Contact Information

This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future / likely events or circumstances.


For further information please contact

Krsnaa Diagnostics

Sujoy Bose, Head- Secretarial, Legal and Compliance

investors@krsnaa.in

Contact: +91 73910 40109



For further information please contact

Krsnaa Diagnostics

Sujoy Bose, Head- Secretarial, Legal and Compliance



investors@krsnaa.in



[Contact: +91 73910 40109](tel:+917391040109)



<https://krsnaadiagnostics.com>